Merkel Cell Carcinoma News and Research

RSS
CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

MD Anderson Cancer Center to host annual Making Cancer History seminar in Sarasota

MD Anderson Cancer Center to host annual Making Cancer History seminar in Sarasota

Progenitor cells responsible for generation and maintenance of Merkel cells

Progenitor cells responsible for generation and maintenance of Merkel cells

New immuno-oncology drug helps body's own immune system to fend off cancer

New immuno-oncology drug helps body's own immune system to fend off cancer

EMD Serono begins MSB0010718C Phase II study in mMCC patients

EMD Serono begins MSB0010718C Phase II study in mMCC patients

OncoSec to present update of data from Phase 2 melanoma study at ASCO Annual Meeting

OncoSec to present update of data from Phase 2 melanoma study at ASCO Annual Meeting

OncoSec Medical to re-launch Phase II cutaneous T-cell lymphoma trial under protocol amendment

OncoSec Medical to re-launch Phase II cutaneous T-cell lymphoma trial under protocol amendment

UV radiation: A central factor behind Queensland’s record rates of Merkel cell carcinoma

UV radiation: A central factor behind Queensland’s record rates of Merkel cell carcinoma

New class of antidepressants appears potentially effective in combating deadly form of lung cancer

New class of antidepressants appears potentially effective in combating deadly form of lung cancer

OncoSec Medical signs Sponsored Research Agreement with ODU for melanoma study

OncoSec Medical signs Sponsored Research Agreement with ODU for melanoma study

Researchers develop multicolor fluorescence labeling method to identify tumor specific miRNAs

Researchers develop multicolor fluorescence labeling method to identify tumor specific miRNAs

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

Regular blood test may help predict survival in patients with Merkel cell carcinoma

Regular blood test may help predict survival in patients with Merkel cell carcinoma

OncoSec establishes UW as second enrolling site for OMS-I100 Phase II metastatic melanoma trial

OncoSec establishes UW as second enrolling site for OMS-I100 Phase II metastatic melanoma trial

OncoSec establishes UCSF as second enrolling site for OMS-I110 Phase II Merkel cell carcinoma trial

OncoSec establishes UCSF as second enrolling site for OMS-I110 Phase II Merkel cell carcinoma trial

VGXI, OncoSec partner to produce interleukin-12 plasmid DNA

VGXI, OncoSec partner to produce interleukin-12 plasmid DNA

Age-adjusted melanoma on the rise

Age-adjusted melanoma on the rise

ImmunoGen commences IMGN901 Phase II evaluation for SCLC

ImmunoGen commences IMGN901 Phase II evaluation for SCLC

OncoSec to commence OMS ElectroImmunotherapy Phase II trial in MCC

OncoSec to commence OMS ElectroImmunotherapy Phase II trial in MCC

OncoSec submits Device Master File for OMS to FDA

OncoSec submits Device Master File for OMS to FDA